{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,22]],"date-time":"2026-08-22T23:22:32Z","timestamp":1787440952997,"version":"build-2736575974"},"reference-count":124,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T00:00:00Z","timestamp":1779148800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","award":["FDN-148413"],"award-info":[{"award-number":["FDN-148413"]}],"id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine &amp; Pharmacotherapy"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.biopha.2026.119551","type":"journal-article","created":{"date-parts":[[2026,5,23]],"date-time":"2026-05-23T07:21:20Z","timestamp":1779520880000},"page":"119551","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Improved brain penetration of neurotensin(8\u201313) via blood-brain barrier shuttle conjugation underlies strong analgesia"],"prefix":"10.1016","volume":"200","author":[{"given":"Camille","family":"Lagard","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9077-6600","authenticated-orcid":false,"given":"J\u00e9r\u00f4me","family":"C\u00f4t\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathan","family":"Meneboo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shauna","family":"Barreto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0671-6283","authenticated-orcid":false,"given":"Michael","family":"Desgagn\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4133-8417","authenticated-orcid":false,"given":"Sabrina","family":"Beaulieu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alain","family":"Larocque","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7473-7043","authenticated-orcid":false,"given":"\u00c9lie","family":"Besserer-Offroy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karine","family":"Belleville","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karyn","family":"Kirby","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3985-2318","authenticated-orcid":false,"given":"Jean-Michel","family":"Longpr\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michel","family":"Demeule","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7627-701X","authenticated-orcid":false,"given":"Philippe","family":"Sarret","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10289","key":"10.1016\/j.biopha.2026.119551_bib1","doi-asserted-by":"crossref","first-page":"2082","DOI":"10.1016\/S0140-6736(21)00393-7","article-title":"Chronic pain: an update on burden, best practices, and new advances","volume":"397","author":"Cohen","year":"2021","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.biopha.2026.119551_bib2","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1111\/hex.12527","article-title":"Patient expectations for management of chronic non-cancer pain: A systematic review","volume":"20","author":"Geurts","year":"2017","journal-title":"Health Expect."},{"issue":"2","key":"10.1016\/j.biopha.2026.119551_bib3","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1097\/SPC.0000000000000495","article-title":"Opioid analgesia: recent developments","volume":"14","author":"Stein","year":"2020","journal-title":"Curr. Opin. Support Palliat. Care"},{"issue":"7","key":"10.1016\/j.biopha.2026.119551_bib4","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1080\/14740338.2016.1177509","article-title":"Safety concerns with long-term opioid use","volume":"15","author":"Harned","year":"2016","journal-title":"Expert Opin. Drug Saf."},{"key":"10.1016\/j.biopha.2026.119551_bib5","doi-asserted-by":"crossref","DOI":"10.1016\/j.ypmed.2023.107777","article-title":"The United States opioid crisis: Big pharma alone is not to blame","volume":"177","author":"Compton","year":"2023","journal-title":"Prev. Med"},{"issue":"4","key":"10.1016\/j.biopha.2026.119551_bib6","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1097\/YCO.0000000000000712","article-title":"The opioid overdose crisis as a global health challenge","volume":"34","author":"Krausz","year":"2021","journal-title":"Curr. Opin. Psychiatry"},{"issue":"5","key":"10.1016\/j.biopha.2026.119551_bib7","doi-asserted-by":"crossref","first-page":"1798","DOI":"10.1021\/jacs.8b09756","article-title":"Chemical Interventions for the Opioid Crisis: Key Advances and Remaining Challenges","volume":"141","author":"Olson","year":"2019","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.biopha.2026.119551_bib8","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.abb.2018.10.011","article-title":"Recent progress in non-opioid analgesic peptides","volume":"660","author":"Perez de Vega","year":"2018","journal-title":"Arch. Biochem Biophys."},{"issue":"1","key":"10.1016\/j.biopha.2026.119551_bib9","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.biopsych.2019.06.017","article-title":"Capturing Novel Non-opioid Pain Targets","volume":"87","author":"Woolf","year":"2020","journal-title":"Biol. Psychiatry"},{"issue":"2","key":"10.1016\/j.biopha.2026.119551_bib10","first-page":"153","article-title":"Receptor and Molecular Targets for the Development of Novel Opioid and Non-Opioid Analgesic Therapies","volume":"24","author":"Chen","year":"2021","journal-title":"Pain. Physician"},{"key":"10.1016\/j.biopha.2026.119551_bib11","doi-asserted-by":"crossref","first-page":"36617","DOI":"10.1038\/srep36617","article-title":"PEPlife: A Repository of the Half-life of Peptides","volume":"6","author":"Mathur","year":"2016","journal-title":"Sci. Rep."},{"issue":"1","key":"10.1016\/j.biopha.2026.119551_bib12","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.drudis.2014.10.003","article-title":"Peptide therapeutics: current status and future directions","volume":"20","author":"Fosgerau","year":"2015","journal-title":"Drug Discov. Today"},{"issue":"4","key":"10.1016\/j.biopha.2026.119551_bib13","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1007\/s10989-023-10524-3","article-title":"Strategic Approaches to Improvise Peptide Drugs as Next Generation Therapeutics","volume":"29","author":"Barman","year":"2023","journal-title":"Int J. Pept. Res Ther."},{"issue":"10","key":"10.1016\/j.biopha.2026.119551_bib14","doi-asserted-by":"crossref","first-page":"2405","DOI":"10.1016\/j.peptides.2006.04.025","article-title":"Neurotensin and pain modulation","volume":"27","author":"Dobner","year":"2006","journal-title":"Peptides"},{"issue":"7","key":"10.1016\/j.biopha.2026.119551_bib15","first-page":"840","article-title":"The roles of neurotensin and its analogues in pain","volume":"21","author":"Feng","year":"2015"},{"issue":"1-3","key":"10.1016\/j.biopha.2026.119551_bib16","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.ejphar.2013.03.004","article-title":"Neurotensin and neurotensin receptors: Characteristic, structure\u2013activity relationship and pain modulation\u2014A review","volume":"716","author":"Kleczkowska","year":"2013","journal-title":"Eur. J. Pharmacol."},{"issue":"6","key":"10.1016\/j.biopha.2026.119551_bib17","doi-asserted-by":"crossref","DOI":"10.1002\/psc.3471","article-title":"Opening the amino acid toolbox for peptide-based NTS2-selective ligands as promising lead compounds for pain management","volume":"29","author":"Previti","year":"2023","journal-title":"J. Pept. Sci."},{"issue":"4","key":"10.1016\/j.biopha.2026.119551_bib18","doi-asserted-by":"crossref","first-page":"2110","DOI":"10.1021\/acs.jmedchem.0c01726","article-title":"Design, Structural Optimization, and Characterization of the First Selective Macrocyclic Neurotensin Receptor Type 2 Non-opioid Analgesic","volume":"64","author":"Chartier","year":"2021","journal-title":"J. Med Chem."},{"key":"10.1016\/j.biopha.2026.119551_bib19","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2021.111861","article-title":"Pharmacodynamic and pharmacokinetic profiles of a neurotensin receptor type 2 (NTS2) analgesic macrocyclic analog","volume":"141","author":"Chartier","year":"2021","journal-title":"Biomed. Pharm."},{"issue":"1","key":"10.1016\/j.biopha.2026.119551_bib20","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/0006-8993(84)90619-X","article-title":"A mechanism for the analgesic effect of neurotensin as revealed by behavioral and electrophysiological techniques","volume":"324","author":"Behbehani","year":"1984","journal-title":"Brain Res"},{"key":"10.1016\/j.biopha.2026.119551_bib21","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/0014-2999(77)90236-9","article-title":"Neurotensin administered intracisternally inhibits responsiveness of mice to noxious stimuli","volume":"46","author":"Clineschmidt","year":"1977","journal-title":"Eur. J. Pharm."},{"key":"10.1016\/j.biopha.2026.119551_bib22","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/0014-2999(79)90415-1","article-title":"Neurotensin: antinocisponsive action in rodents","volume":"54","author":"Clineschmidt","year":"1979","journal-title":"Eur. J. Pharm."},{"issue":"3","key":"10.1016\/j.biopha.2026.119551_bib23","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/S0022-3565(25)32585-1","article-title":"Jr., Neurotensin-induced antinociception in mice: antagonism by thyrotropin-releasing hormone","volume":"217","author":"Osbahr","year":"1981","journal-title":"J. Pharm. Exp. Ther."},{"issue":"1-2","key":"10.1016\/j.biopha.2026.119551_bib24","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/0006-8993(91)90139-M","article-title":"Structure-antinociceptive activity of neurotensin and some novel analogues in the periaqueductal gray region of the brainstem","volume":"557","author":"al-Rodhan","year":"1991","journal-title":"Brain Res"},{"issue":"5-6","key":"10.1016\/j.biopha.2026.119551_bib25","first-page":"481","article-title":"Pharmacological interaction between neuropeptides and pethidine or fentanyl in rat spinal cord","volume":"45","author":"Herman","year":"1993","journal-title":"Pol. J. Pharm."},{"issue":"5-6","key":"10.1016\/j.biopha.2026.119551_bib26","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1097\/FBP.0b013e3283474a3a","article-title":"Analgesic synergy of neurotensin receptor subtype 2 agonist NT79 and morphine","volume":"22","author":"Boules","year":"2011","journal-title":"Behav. Pharm."},{"key":"10.1016\/j.biopha.2026.119551_bib27","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.brainres.2009.07.086","article-title":"NT69L, a novel analgesic, shows synergy with morphine","volume":"1294","author":"Boules","year":"2009","journal-title":"Brain Res."},{"key":"10.1016\/j.biopha.2026.119551_bib28","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.ejphar.2019.01.048","article-title":"The combination of opioid and neurotensin receptor agonists improves their analgesic\/adverse effect ratio","volume":"848","author":"Eiselt","year":"2019","journal-title":"Eur. J. Pharmacol."},{"issue":"4","key":"10.1016\/j.biopha.2026.119551_bib29","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1038\/s41573-019-0053-0","article-title":"Advances in oral peptide therapeutics","volume":"19","author":"Drucker","year":"2020","journal-title":"Nat. Rev. Drug Discov."},{"issue":"1","key":"10.1016\/j.biopha.2026.119551_bib30","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1038\/s41392-022-00904-4","article-title":"Therapeutic peptides: current applications and future directions","volume":"7","author":"Wang","year":"2022","journal-title":"Signal Transduct. Target Ther."},{"issue":"1","key":"10.1016\/j.biopha.2026.119551_bib31","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1602\/neurorx.2.1.3","article-title":"The blood-brain barrier: bottleneck in brain drug development","volume":"2","author":"Pardridge","year":"2005","journal-title":"NeuroRx"},{"issue":"9","key":"10.1016\/j.biopha.2026.119551_bib32","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics14091874","article-title":"Peptide Shuttles for Blood-Brain Barrier Drug Delivery","volume":"14","author":"Sanchez-Navarro","year":"2022","journal-title":"Pharmaceutics"},{"issue":"1","key":"10.1016\/j.biopha.2026.119551_bib33","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.nbd.2009.07.028","article-title":"Approaches to transport therapeutic drugs across the blood\u2013brain barrier to treat brain diseases","volume":"37","author":"Gabathuler","year":"2010","journal-title":"Neurobiol. Dis."},{"issue":"8","key":"10.1016\/j.biopha.2026.119551_bib34","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1517\/14728222.2015.1042364","article-title":"Blood\u2013brain barrier endogenous transporters as therapeutic targets: a new model for small molecule CNS drug discovery","volume":"19","author":"Pardridge","year":"2015","journal-title":"Expert Opin. Ther. Targets"},{"issue":"4","key":"10.1016\/j.biopha.2026.119551_bib35","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1021\/mp400680d","article-title":"Strategies To Deliver Peptide Drugs to the Brain","volume":"11","author":"Lalatsa","year":"2014","journal-title":"Mol. Pharm."},{"issue":"4","key":"10.1016\/j.biopha.2026.119551_bib36","doi-asserted-by":"crossref","first-page":"1534","DOI":"10.1111\/j.1471-4159.2008.05492.x","article-title":"Involvement of the low-density lipoprotein receptor-related protein in the transcytosis of the brain delivery vector Angiopep-2","volume":"106","author":"Demeule","year":"2008","journal-title":"J. Neurochem."},{"issue":"3","key":"10.1016\/j.biopha.2026.119551_bib37","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1124\/jpet.107.131318","article-title":"Identification and Design of Peptides as a New Drug Delivery System for the Brain","volume":"324","author":"Demeule","year":"2008","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"12","key":"10.1016\/j.biopha.2026.119551_bib38","doi-asserted-by":"crossref","first-page":"2827","DOI":"10.1111\/j.1582-4934.2009.00930.x","article-title":"Transport characteristics of a novel peptide platform for CNS therapeutics","volume":"14","author":"Bertrand","year":"2010","journal-title":"J. Cell Mol. Med"},{"issue":"2","key":"10.1016\/j.biopha.2026.119551_bib39","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1038\/bjp.2008.260","article-title":"Antitumour activity of ANG1005, a conjugate between paclitaxel and the new brain delivery vector Angiopep-2","volume":"155","author":"Regina","year":"2008","journal-title":"Br. J. Pharm."},{"issue":"7","key":"10.1016\/j.biopha.2026.119551_bib40","doi-asserted-by":"crossref","first-page":"2814","DOI":"10.1021\/jm9016637","article-title":"New Angiopep-modified doxorubicin (ANG1007) and etoposide (ANG1009) chemotherapeutics with increased brain penetration","volume":"53","author":"Che","year":"2010","journal-title":"J. Med Chem."},{"issue":"6","key":"10.1016\/j.biopha.2026.119551_bib41","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1158\/1078-0432.CCR-12-2481","article-title":"Phase I study of GRN1005 in recurrent malignant glioma","volume":"19","author":"Drappatz","year":"2013","journal-title":"Clin. Cancer Res"},{"issue":"11","key":"10.1016\/j.biopha.2026.119551_bib42","doi-asserted-by":"crossref","first-page":"2486","DOI":"10.1007\/s11095-009-9964-5","article-title":"Uptake of ANG1005, a novel paclitaxel derivative, through the blood-brain barrier into brain and experimental brain metastases of breast cancer","volume":"26","author":"Thomas","year":"2009","journal-title":"Pharm. Res"},{"issue":"1","key":"10.1016\/j.biopha.2026.119551_bib43","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1124\/jpet.119.263566","article-title":"Use of a Noninvasive Brain-Penetrating Peptide-Drug Conjugate Strategy to Improve the Delivery of Opioid Pain Relief Medications to the Brain","volume":"374","author":"Eiselt","year":"2020","journal-title":"J. Pharm. Exp. Ther."},{"issue":"3","key":"10.1016\/j.biopha.2026.119551_bib44","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1172\/JCI70647","article-title":"Conjugation of a brain-penetrant peptide with neurotensin provides antinociceptive properties","volume":"124","author":"Demeule","year":"2014","journal-title":"J. Clin. Investig."},{"issue":"1","key":"10.1016\/j.biopha.2026.119551_bib45","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1158\/1535-7163.MCT-14-0399","article-title":"ANG4043, a novel brain-penetrant peptide-mAb conjugate, is efficacious against HER2-positive intracranial tumors in mice","volume":"14","author":"Regina","year":"2015","journal-title":"Mol. Cancer Ther."},{"issue":"6","key":"10.1016\/j.biopha.2026.119551_bib46","doi-asserted-by":"crossref","first-page":"3359","DOI":"10.1039\/D1RA08131D","article-title":"Homogeneous antibody-angiopep 2 conjugates for effective brain targeting","volume":"12","author":"Anami","year":"2022","journal-title":"RSC Adv."},{"issue":"20","key":"10.1016\/j.biopha.2026.119551_bib47","doi-asserted-by":"crossref","first-page":"2503","DOI":"10.2217\/nnm-2017-0181","article-title":"Improving gold nanorod delivery to the central nervous system by conjugation to the shuttle Angiopep-2","volume":"12","author":"Velasco-Aguirre","year":"2017","journal-title":"Nanomed. (Lond. )"},{"issue":"33","key":"10.1016\/j.biopha.2026.119551_bib48","doi-asserted-by":"crossref","first-page":"8669","DOI":"10.1016\/j.biomaterials.2011.07.069","article-title":"A cascade targeting strategy for brain neuroglial cells employing nanoparticles modified with angiopep-2 peptide and EGFP-EGF1 protein","volume":"32","author":"Huile","year":"2011","journal-title":"Biomaterials"},{"issue":"11","key":"10.1016\/j.biopha.2026.119551_bib49","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1038\/bjc.2011.427","article-title":"Influence of glioma tumour microenvironment on the transport of ANG1005 via low-density lipoprotein receptor-related protein 1","volume":"105","author":"Bertrand","year":"2011","journal-title":"Br. J. Cancer"},{"issue":"2","key":"10.1016\/j.biopha.2026.119551_bib50","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1158\/1535-7163.MCT-11-0566","article-title":"Safety, pharmacokinetics, and activity of GRN1005, a novel conjugate of angiopep-2, a peptide facilitating brain penetration, and paclitaxel, in patients with advanced solid tumors","volume":"11","author":"Kurzrock","year":"2012","journal-title":"Mol. Cancer Ther."},{"issue":"12","key":"10.1016\/j.biopha.2026.119551_bib51","doi-asserted-by":"crossref","first-page":"2789","DOI":"10.1158\/1078-0432.CCR-19-3258","article-title":"ANG1005, a Brain-Penetrating Peptide-Drug Conjugate, Shows Activity in Patients with Breast Cancer with Leptomeningeal Carcinomatosis and Recurrent Brain Metastases","volume":"26","author":"Kumthekar","year":"2020","journal-title":"Clin. Cancer Res"},{"issue":"1","key":"10.1016\/j.biopha.2026.119551_bib52","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1007\/s10549-016-3972-z","article-title":"ANG1005 for breast cancer brain metastases: correlation between (18)F-FLT-PET after first cycle and MRI in response assessment","volume":"160","author":"O'Sullivan","year":"2016","journal-title":"Breast Cancer Res Treat."},{"issue":"1-2","key":"10.1016\/j.biopha.2026.119551_bib53","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/S0014-2999(99)00877-8","article-title":"Highly potent neurotensin analog that causes hypothermia and antinociception","volume":"390","author":"Tyler-McMahon","year":"2000","journal-title":"Eur. J. Pharmacol."},{"issue":"7","key":"10.1016\/j.biopha.2026.119551_bib54","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1021\/jm801072v","article-title":"Comparison of N-terminal modifications on neurotensin(8-13) analogues correlates peptide stability but not binding affinity with in vivo efficacy","volume":"52","author":"Orwig","year":"2009","journal-title":"J. Med Chem."},{"issue":"12","key":"10.1016\/j.biopha.2026.119551_bib55","doi-asserted-by":"crossref","first-page":"4623","DOI":"10.1021\/jm100092s","article-title":"Identification and Functional Characterization of a Stable, Centrally Active Derivative of the Neurotensin (8\u221213) Fragment as a Potential First-in-Class Analgesic","volume":"53","author":"Hughes","year":"2010","journal-title":"J. Med. Chem."},{"issue":"3","key":"10.1016\/j.biopha.2026.119551_bib56","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1124\/jpet.109.165282","article-title":"Systemically and Topically Active Antinociceptive Neurotensin Compounds","volume":"334","author":"Rossi","year":"2010","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"19","key":"10.1016\/j.biopha.2026.119551_bib57","doi-asserted-by":"crossref","first-page":"7785","DOI":"10.1021\/acs.jmedchem.5b00841","article-title":"Synthesis and Characterization in Vitro and in Vivo of (l)-(Trimethylsilyl)alanine Containing Neurotensin Analogues","volume":"58","author":"Fanelli","year":"2015","journal-title":"J. Med. Chem."},{"issue":"1","key":"10.1016\/j.biopha.2026.119551_bib58","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1016\/j.bmc.2016.10.039","article-title":"NTS2-selective neurotensin mimetics with tetrahydrofuran amino acids","volume":"25","author":"Simeth","year":"2017","journal-title":"Bioorg. & Med. Chem."},{"issue":"11","key":"10.1016\/j.biopha.2026.119551_bib59","doi-asserted-by":"crossref","first-page":"4535","DOI":"10.1021\/acschemneuro.9b00390","article-title":"Neurotensin Analogues Containing Cyclic Surrogates of Tyrosine at Position 11 Improve NTS2 Selectivity Leading to Analgesia without Hypotension and Hypothermia","volume":"10","author":"Eiselt","year":"2019","journal-title":"ACS Chem. Neurosci."},{"issue":"1","key":"10.1016\/j.biopha.2026.119551_bib60","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/0006-8993(95)00836-F","article-title":"Permeability of the blood-brain barrier to the neurotensin8\u201313 analog NT1","volume":"695","author":"Banks","year":"1995","journal-title":"Brain Res."},{"issue":"1","key":"10.1016\/j.biopha.2026.119551_bib61","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1002\/cmdc.201200376","article-title":"Development of a Metabolically Stable Neurotensin Receptor 2 (NTS2) Ligand","volume":"8","author":"Held","year":"2013","journal-title":"ChemMedChem"},{"key":"10.1016\/j.biopha.2026.119551_bib62","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejphar.2017.03.046","article-title":"The signaling signature of the neurotensin type 1 receptor with endogenous ligands","volume":"805","author":"Besserer-Offroy","year":"2017","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.biopha.2026.119551_bib63","first-page":"8","article-title":"Elucidation of the StructureActivity Relationships of Apelin: Influence of Unnatural Amino Acids on Binding","author":"Murza","year":"2012","journal-title":"Signal. Plasma Stab."},{"issue":"16","key":"10.1016\/j.biopha.2026.119551_bib64","doi-asserted-by":"crossref","first-page":"7103","DOI":"10.1021\/acs.jmedchem.8b00175","article-title":"Structural Optimization and Characterization of Potent Analgesic Macrocyclic Analogues of Neurotensin (8\u201313)","volume":"61","author":"Sousbie","year":"2018","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.biopha.2026.119551_bib65","first-page":"3644","article-title":"Fast, accurate and versatile Monte Carlo method for computing system matrix","author":"Leroux","year":"2007","journal-title":"IEEE Nucl. Sci. Conf. Rec."},{"issue":"1","key":"10.1016\/j.biopha.2026.119551_bib66","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/0304-3959(92)90003-T","article-title":"The formalin test: an evaluation of the method","volume":"51","author":"Tj\u00f8lsen","year":"1992","journal-title":"Pain"},{"issue":"1","key":"10.1016\/j.biopha.2026.119551_bib67","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/0304-3959(88)90209-6","article-title":"A peripheral mononeuropathy in rat that produces disorders of pain sensation like those seen in man","volume":"33","author":"Bennett","year":"1988","journal-title":"Pain"},{"issue":"3","key":"10.1016\/j.biopha.2026.119551_bib68","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1016\/0034-5687(70)90056-3","article-title":"Control of breathing in experimental anemia","volume":"10","author":"Bartlett","year":"1970","journal-title":"Respir. Physiol."},{"issue":"4","key":"10.1016\/j.biopha.2026.119551_bib69","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/0014-2999(78)90140-1","article-title":"Effects of neurotensin on isolated intestinal smooth muscles","volume":"50","author":"Kitabgi","year":"1978","journal-title":"Eur. J. Pharm."},{"issue":"5 Pt 1","key":"10.1016\/j.biopha.2026.119551_bib70","first-page":"G767","article-title":"Mechanisms of neurotensin-induced inhibition in rat ileal smooth muscle","volume":"263","author":"Allescher","year":"1992","journal-title":"Am. J. Physiol."},{"issue":"5","key":"10.1016\/j.biopha.2026.119551_bib71","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/0301-0082(93)90044-S","article-title":"Spatial and temporal aspects of spinal cord and brainstem activation in the formalin pain model","volume":"41","author":"Porro","year":"1993","journal-title":"Prog. Neurobiol."},{"issue":"1-2","key":"10.1016\/j.biopha.2026.119551_bib72","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/S0304-3959(03)00015-0","article-title":"Independent time courses of supraspinal nociceptive activity and spinally mediated behavior during tonic pain","volume":"104","author":"Porro","year":"2003","journal-title":"Pain"},{"key":"10.1016\/j.biopha.2026.119551_bib73","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1186\/1744-8069-5-38","article-title":"Evidence for a role of NTS2 receptors in the modulation of tonic pain sensitivity","volume":"5","author":"Roussy","year":"2009","journal-title":"Mol. Pain."},{"issue":"4","key":"10.1016\/j.biopha.2026.119551_bib74","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/j.ejpain.2011.07.008","article-title":"Intrathecal administration of NTS 1 agonists reverses nociceptive behaviors in a rat model of neuropathic pain","volume":"16","author":"Guillemette","year":"2012","journal-title":"Eur. J. Pain."},{"issue":"9","key":"10.1016\/j.biopha.2026.119551_bib75","doi-asserted-by":"crossref","first-page":"3741","DOI":"10.1096\/fj.12-225540","article-title":"Spinal NTS2 receptor activation reverses signs of neuropathic pain","volume":"27","author":"T\u00e9treault","year":"2013","journal-title":"FASEB J."},{"issue":"2","key":"10.1016\/j.biopha.2026.119551_bib76","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.pbb.2004.12.005","article-title":"Antinociceptive, hypothermic, hypotensive, and reinforcing effects of a novel neurotensin receptor agonist, NT69L, in rhesus monkeys","volume":"80","author":"Fantegrossi","year":"2005","journal-title":"Pharmacol. Biochem. Behav."},{"issue":"19","key":"10.1016\/j.biopha.2026.119551_bib77","first-page":"6854","article-title":"The Isolation of a New Hypotensive Peptide, Neurotensin, from Bovine Hypothalami","volume":"248","author":"Carraway","year":"1973"},{"issue":"1","key":"10.1016\/j.biopha.2026.119551_bib78","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1124\/jpet.300.1.305","article-title":"The effects of deleting the mouse neurotensin receptor NTR1 on central and peripheral responses to neurotensin","volume":"300","author":"Pettibone","year":"2002","journal-title":"J. Pharm. Exp. Ther."},{"issue":"19","key":"10.1016\/j.biopha.2026.119551_bib79","doi-asserted-by":"crossref","first-page":"10706","DOI":"10.1073\/pnas.1834523100","article-title":"The conformation of neurotensin bound to its G protein-coupled receptor","volume":"100","author":"Luca","year":"2003","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.biopha.2026.119551_bib80","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.bpc.2012.06.003","article-title":"Modulation of the neurotensin solution structure in the presence of ganglioside GM1 bicelle","volume":"168-169","author":"Khatun","year":"2012","journal-title":"Biophys. Chem."},{"issue":"8","key":"10.1016\/j.biopha.2026.119551_bib81","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1080\/07391102.2012.712459","article-title":"Elucidation by NMR solution of neurotensin in small unilamellar vesicle environment: molecular surveys for neurotensin receptor recognition","volume":"31","author":"Costa","year":"2013","journal-title":"J. Biomol. Struct. Dyn."},{"issue":"1","key":"10.1016\/j.biopha.2026.119551_bib82","doi-asserted-by":"crossref","first-page":"8155","DOI":"10.1038\/s41467-023-44010-7","article-title":"Unravelling the mechanism of neurotensin recognition by neurotensin receptor 1","volume":"14","author":"Asadollahi","year":"2023","journal-title":"Nat. Commun."},{"issue":"25","key":"10.1016\/j.biopha.2026.119551_bib83","doi-asserted-by":"crossref","first-page":"15060","DOI":"10.1074\/jbc.271.25.15060","article-title":"Proposed Ligand Binding Site of the Transmembrane Receptor for Neurotensin(8\u201313)","volume":"271","author":"Pang","year":"1996","journal-title":"J. Biol. Chem."},{"issue":"1","key":"10.1016\/j.biopha.2026.119551_bib84","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1074\/jbc.275.1.328","article-title":"Identification of Residues Involved in Neurotensin Binding and Modeling of the Agonist Binding Site in Neurotensin Receptor 1","volume":"275","author":"Barroso","year":"2000","journal-title":"J. Biol. Chem."},{"issue":"22","key":"10.1016\/j.biopha.2026.119551_bib85","doi-asserted-by":"crossref","first-page":"5587","DOI":"10.1021\/jm049644y","article-title":"Evaluation of Lactam-Bridged Neurotensin Analogues Adjusting \u03c8(Pro 10) Close to the Experimentally Derived Bioactive Conformation of NT(8\u221213)","volume":"47","author":"Bittermann","year":"2004","journal-title":"J. Med. Chem."},{"issue":"6","key":"10.1016\/j.biopha.2026.119551_bib86","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.1016\/j.bmcl.2008.01.110","article-title":"Peptide backbone modifications on the C-terminal hexapeptide of neurotensin","volume":"18","author":"Einsiedel","year":"2008","journal-title":"Bioorg. & Med. Chem. Lett."},{"issue":"6","key":"10.1016\/j.biopha.2026.119551_bib87","doi-asserted-by":"crossref","first-page":"E655","DOI":"10.1073\/pnas.1317903111","article-title":"Structure of signaling-competent neurotensin receptor 1 obtained by directed evolution in Escherichia coli","volume":"111","author":"Egloff","year":"2014","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"15","key":"10.1016\/j.biopha.2026.119551_bib88","doi-asserted-by":"crossref","first-page":"4917","DOI":"10.1021\/jp510735f","article-title":"Structural Dynamics and Thermostabilization of Neurotensin Receptor 1","volume":"119","author":"Lee","year":"2015","journal-title":"J. Phys. Chem. B"},{"issue":"1","key":"10.1016\/j.biopha.2026.119551_bib89","doi-asserted-by":"crossref","DOI":"10.1038\/srep38564","article-title":"Structure and dynamics of a constitutively active neurotensin receptor","volume":"6","author":"Krumm","year":"2016","journal-title":"Sci. Rep."},{"issue":"7421","key":"10.1016\/j.biopha.2026.119551_bib90","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1038\/nature11558","article-title":"Structure of the agonist-bound neurotensin receptor","volume":"490","author":"White","year":"2012","journal-title":"Nature"},{"issue":"5","key":"10.1016\/j.biopha.2026.119551_bib91","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.abe5504","article-title":"Complexes of the neurotensin receptor 1 with small-molecule ligands reveal structural determinants of full, partial, and inverse agonism","volume":"7","author":"Deluigi","year":"2021","journal-title":"Sci. Adv."},{"issue":"7767","key":"10.1016\/j.biopha.2026.119551_bib92","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1038\/s41586-019-1337-6","article-title":"Conformational transitions of a neurotensin receptor 1-G(i1) complex","volume":"572","author":"Kato","year":"2019","journal-title":"Nature"},{"issue":"10","key":"10.1016\/j.biopha.2026.119551_bib93","doi-asserted-by":"crossref","first-page":"3261","DOI":"10.1021\/mp500086e","article-title":"Retro-Inverso Isomer of Angiopep-2: A Stable d -Peptide Ligand Inspires Brain-Targeted Drug Delivery","volume":"11","author":"Wei","year":"2014","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.biopha.2026.119551_bib94","first-page":"145","article-title":"The formalin test: characteristics and usefulness of the model","volume":"7","author":"S.J.a.L.X","year":"2004","journal-title":"Rev. Analg."},{"issue":"17","key":"10.1016\/j.biopha.2026.119551_bib95","doi-asserted-by":"crossref","first-page":"18064","DOI":"10.1021\/acs.jmedchem.5c01126","article-title":"Current Nonopioid Small Molecule Approaches Toward the Treatment of Neuropathic Pain","volume":"68","author":"Cioffi","year":"2025","journal-title":"J. Med Chem."},{"issue":"1","key":"10.1016\/j.biopha.2026.119551_bib96","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1146\/annurev-pharmtox-010818-021511","article-title":"Systems Pharmacology: Defining the Interactions of Drug Combinations","volume":"59","author":"van Hasselt","year":"2019","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"10.1016\/j.biopha.2026.119551_bib97","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.brainres.2009.10.050","article-title":"NT79: A novel neurotensin analog with selective behavioral effects","volume":"1308","author":"Boules","year":"2010","journal-title":"Brain Res."},{"key":"10.1016\/j.biopha.2026.119551_bib98","doi-asserted-by":"crossref","DOI":"10.1186\/1744-8069-6-86","article-title":"PK20, a New Opioid-Neurotensin Hybrid Peptide That Exhibits Central and Peripheral Antinociceptive Effects","volume":"6","author":"Kleczkowska","year":"2010","journal-title":"Mol. Pain."},{"issue":"21","key":"10.1016\/j.biopha.2026.119551_bib99","doi-asserted-by":"crossref","first-page":"12929","DOI":"10.1021\/acs.jmedchem.0c01376","article-title":"Optimized Opioid-Neurotensin Multitarget Peptides: From Design to Structure-Activity Relationship Studies","volume":"63","author":"Gonzalez","year":"2020","journal-title":"J. Med Chem."},{"issue":"9","key":"10.1016\/j.biopha.2026.119551_bib100","doi-asserted-by":"crossref","first-page":"2784","DOI":"10.1021\/acsptsci.4c00236","article-title":"Design, Synthesis, and In Vitro Characterization of Proteolytically-Stable Opioid-Neurotensin Hybrid Peptidomimetics","volume":"7","author":"De Neve","year":"2024","journal-title":"ACS Pharm. Transl. Sci."},{"key":"10.1016\/j.biopha.2026.119551_bib101","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2024.107408","article-title":"Multitarget ligands that comprise opioid\/nonopioid pharmacophores for pain management: Current state of the science","volume":"209","author":"Breault","year":"2024","journal-title":"Pharm. Res"},{"issue":"6","key":"10.1016\/j.biopha.2026.119551_bib102","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics14061283","article-title":"A Historical Review of Brain Drug Delivery","volume":"14","author":"Pardridge","year":"2022","journal-title":"Pharmaceutics"},{"issue":"6","key":"10.1016\/j.biopha.2026.119551_bib103","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1007\/s40259-017-0248-z","article-title":"Delivery of Biologics Across the Blood-Brain Barrier with Molecular Trojan Horse Technology","volume":"31","author":"Pardridge","year":"2017","journal-title":"BioDrugs"},{"key":"10.1016\/j.biopha.2026.119551_bib104","doi-asserted-by":"crossref","first-page":"373","DOI":"10.3389\/fnagi.2019.00373","article-title":"Blood-Brain Barrier and Delivery of Protein and Gene Therapeutics to Brain","volume":"11","author":"Pardridge","year":"2019","journal-title":"Front Aging Neurosci."},{"issue":"1","key":"10.1016\/j.biopha.2026.119551_bib105","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics15010093","article-title":"Advanced Blood-Brain Barrier Drug Delivery","volume":"15","author":"Pardridge","year":"2022","journal-title":"Pharmaceutics"},{"issue":"4064","key":"10.1016\/j.biopha.2026.119551_bib106","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1126\/science.178.4064.984","article-title":"Blood-brain barrier: penetration of morphine, codeine, heroin, and methadone after carotid injection","volume":"178","author":"Oldendorf","year":"1972","journal-title":"Science"},{"issue":"1","key":"10.1016\/j.biopha.2026.119551_bib107","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/0196-9781(94)90165-1","article-title":"Opposite direction of transport across the blood-brain barrier for Tyr-MIF-1 and MIF-1: comparison with morphine","volume":"15","author":"Banks","year":"1994","journal-title":"Peptides"},{"issue":"6","key":"10.1016\/j.biopha.2026.119551_bib108","first-page":"768","article-title":"Blood-brain barrier permeability to morphine-6-glucuronide is markedly reduced compared with morphine","volume":"25","author":"Wu","year":"1997","journal-title":"Drug Metab. Dispos."},{"issue":"2","key":"10.1016\/j.biopha.2026.119551_bib109","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/j.apsb.2018.12.001","article-title":"Dual-targeting and microenvironment-responsive micelles as a gene delivery system to improve the sensitivity of glioma to radiotherapy","volume":"9","author":"Jiao","year":"2019","journal-title":"Acta Pharm. Sin. B"},{"issue":"1","key":"10.1016\/j.biopha.2026.119551_bib110","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.pharmthera.2012.07.008","article-title":"Low-density lipoprotein receptor-related protein 1: a physiological Abeta homeostatic mechanism with multiple therapeutic opportunities","volume":"136","author":"Sagare","year":"2012","journal-title":"Pharm. Ther."},{"key":"10.1016\/j.biopha.2026.119551_bib111","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1016\/j.neuropharm.2016.03.051","article-title":"Blood-brain barrier transport kinetics of the neuromedin peptides NMU, NMN, NMB and NT","volume":"107","author":"Gevaert","year":"2016","journal-title":"Neuropharmacology"},{"issue":"1-2","key":"10.1016\/j.biopha.2026.119551_bib112","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/S0006-8993(02)03271-7","article-title":"Targeted inactivation of the neurotensin type 1 receptor reveals its role in body temperature control and feeding behavior but not in analgesia","volume":"953","author":"Remaury","year":"2002","journal-title":"Brain Res"},{"key":"10.1016\/j.biopha.2026.119551_bib113","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1111\/j.1749-6632.1982.tb31575.x","article-title":"Neurotensin and thermoregulation","volume":"400","author":"Bissette","year":"1982","journal-title":"Ann. N. Y Acad. Sci."},{"issue":"1-2","key":"10.1016\/j.biopha.2026.119551_bib114","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.resp.2010.07.009","article-title":"The effects of baroreceptor stimulation on central respiratory drive: A review","volume":"174","author":"McMullan","year":"2010","journal-title":"Respir. Physiol. & Neurobiol."},{"key":"10.1016\/j.biopha.2026.119551_bib115","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2022.824395","article-title":"Physiological Changes in Subjects Exposed to Accidental Hypothermia: An Update","volume":"9","author":"Bjertnaes","year":"2022","journal-title":"Front Med"},{"issue":"1","key":"10.1016\/j.biopha.2026.119551_bib116","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/0006-8993(86)91225-4","article-title":"The excitation by neurotensin of nucleus tractus solitarius neurons induces apneustic breathing","volume":"384","author":"Morin-Surun","year":"1986","journal-title":"Brain Res"},{"issue":"1","key":"10.1016\/j.biopha.2026.119551_bib117","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1002\/(SICI)1096-9861(19960909)373:1<76::AID-CNE7>3.0.CO;2-A","article-title":"Cellular distribution of neurotensin receptors in rat brain: immunohistochemical study using an antipeptide antibody against the cloned high affinity receptor","volume":"373","author":"Boudin","year":"1996","journal-title":"J. Comp. Neurol."},{"issue":"1","key":"10.1016\/j.biopha.2026.119551_bib118","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/0306-4522(87)90282-X","article-title":"Distribution of neurotensin binding sites in the caudal brainstem of the rat: a light microscopic radioautographic study","volume":"23","author":"Kessler","year":"1987","journal-title":"Neuroscience"},{"issue":"8","key":"10.1016\/j.biopha.2026.119551_bib119","doi-asserted-by":"crossref","first-page":"2915","DOI":"10.1021\/jm200006c","article-title":"Discovery of highly potent and neurotensin receptor 2 selective neurotensin mimetics","volume":"54","author":"Einsiedel","year":"2011","journal-title":"J. Med Chem."},{"issue":"1","key":"10.1016\/j.biopha.2026.119551_bib120","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1002\/cmdc.201200376","article-title":"Development of a metabolically stable neurotensin receptor 2 (NTS2) ligand","volume":"8","author":"Held","year":"2013","journal-title":"ChemMedChem"},{"issue":"5","key":"10.1016\/j.biopha.2026.119551_bib121","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1002\/cmdc.201300054","article-title":"Impact of the proline residue on ligand binding of neurotensin receptor 2 (NTS2)-selective peptide-peptoid hybrids","volume":"8","author":"Held","year":"2013","journal-title":"ChemMedChem"},{"issue":"10","key":"10.1016\/j.biopha.2026.119551_bib122","doi-asserted-by":"crossref","first-page":"3746","DOI":"10.1039\/c1ob05292f","article-title":"Radical arylation of tyrosine and its application in the synthesis of a highly selective neurotensin receptor 2 ligand","volume":"9","author":"Pratsch","year":"2011","journal-title":"Org. Biomol. Chem."},{"issue":"5","key":"10.1016\/j.biopha.2026.119551_bib123","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1002\/open.201402031","article-title":"Structure-based evolution of subtype-selective neurotensin receptor ligands","volume":"3","author":"Schaab","year":"2014","journal-title":"ChemistryOpen"},{"issue":"47","key":"10.1016\/j.biopha.2026.119551_bib124","doi-asserted-by":"crossref","DOI":"10.1002\/anie.202405941","article-title":"Development of Macrocyclic Neurotensin Receptor Type 2 (NTS2) Opioid-Free Analgesics","volume":"63","author":"Desgagne","year":"2024","journal-title":"Angew. Chem. Int Ed. Engl."}],"container-title":["Biomedicine &amp; Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332226005871?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332226005871?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,22]],"date-time":"2026-08-22T22:57:42Z","timestamp":1787439462000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0753332226005871"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":124,"alternative-id":["S0753332226005871"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2026.119551","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Improved brain penetration of neurotensin(8\u201313) via blood-brain barrier shuttle conjugation underlies strong analgesia","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2026.119551","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"119551"}}